Nuclear Medicine Radioisotopes Market Report 2026

Nuclear Medicine Radioisotopes Market Overview

• Nuclear Medicine Radioisotopes market size has reached to $8.85 billion in 2025 • Expected to grow to $12.75 billion in 2030 at a compound annual growth rate (CAGR) of 7.4% • Growth Driver: Rising Cases Of Cardiovascular Diseases Is Driving The Growth Of The Nuclear Medicine Radioisotopes • Market Trend: Next-Generation Radiopharmaceuticals Accelerate The Future Of Precision Medicine • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Nuclear Medicine Radioisotopes Market?

Nuclear medicine radioisotopes are radioactive isotopes used in nuclear medicine to diagnose, treat, and research various medical conditions. These isotopes emit radiation detected and imaged by specialized equipment or deliver therapeutic doses of radiation to targeted tissues. Nuclear medicine radioisotopes are essential in modern medical diagnostics and treatments, providing critical information and therapeutic options that improve patient outcomes. The main types of nuclear medicine radioisotopes are technetium-99m (Tc-99m), thallium-201 (Tl-201), iodine (I-123), fluorine-18, rubidium-82 (Rb-82), iodine-131 (I-131), lutetium-177 (Lu-177), radium-223 (Ra-223) and alpharadin, actinium-225 (Ac-225), and others. Technetium-99m (Tc-99m) is a radioactive isotope widely used in nuclear medicine imaging procedures to diagnose various medical conditions. Applications such as oncology, cardiology, thyroid, neurology, and others for end users such as hospitals, diagnostic centers, specialty clinics, education and research institutes, and others.

What Is The Nuclear Medicine Radioisotopes Market Growth Forecast?

The nuclear medicine radioisotopes market size is expected to see strong growth in the next few years. It will grow to $12.75 billion in 2030 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to rising demand for personalized cancer treatment, increasing use of lutetium-177 and actinium-225 therapies, expansion of PET imaging infrastructure, growing investments in cyclotron and reactor facilities, rising adoption of nuclear medicine in emerging economies. Major trends in the forecast period include rising adoption of theranostics in oncology care, growing demand for PET and SPECT imaging procedures, increased use of targeted alpha and beta emitters, expansion of nuclear medicine in cardiology and neurology, strengthening focus on domestic radioisotope production.

Global Nuclear Medicine Radioisotopes Market Segmentation

1) By Type: Technetium-99m (Tc-99m), Thallium-201 (Tl-201), Iodine (I-123), Fluorine-18, Rubidium-82 (Rb-82), Iodine-131 (I-131), Lutetium-177 (Lu-177), Radium-223 (Ra-223) And Alpharadin, Other Types 2) By Application: Oncology, Cardiology, Thyroid, Neurology, Other Applications 3) By End-User: Hospitals, Diagnostic Centers, Specialty Clinics, Education And Research Institutes, Other End-Users Subsegments: 1) By Technetium-99m (Tc-99m): Sodium Pertechnetate Tc-99m, Tc-99m MDP (Methylene Diphosphonate), Tc-99m HMPAO (Hexamethylpropyleneamine oxime) 2) By Thallium-201 (Tl-201): Thallous Chloride Tl-201, Thallium-201 for Cardiac Imaging 3) By Iodine-123 (I-123): Iodine-123 Sodium Iodide, Iodine-123 Ioflupane (DaTscan) 4) By Fluorine-18: FDG (Fluorodeoxyglucose) F-18, Fluoride-18 For Bone Imaging 5) By Rubidium-82 (Rb-82): Rb-82 For PET (Positron Emission Tomography) Imaging, Rb-82 For Cardiac Imaging 6) By Iodine-131 (I-131): I-131 Sodium Iodide, I-131 For Thyroid Cancer Treatment, I-131 For Hyperthyroidism Treatment 7) By Lutetium-177 (Lu-177): Lu-177-DOTATATE, Lu-177 For Prostate Cancer Treatment 8) By Radium-223 (Ra-223): Ra-223 Dichloride (Xofigo), Alpharadin For Bone Metastasis Treatment 9) By Alpharadin (Radium-223 Alpha Emitters): Ac-225 For Targeted Alpha Therapy (TAT), Ac-225 For Cancer Treatment, Gallium-68 (Ga-68), Copper-64 (Cu-64), Yttrium-90 (Y-90) 10) By Other Types: Ac-225 For Targeted Alpha Therapy (TAT), Ac-225 For Cancer Treatment, Gallium-68 (Ga-68), Copper-64 (Cu-64), Yttrium-90 (Y-90)

What Is The Driver Of The Nuclear Medicine Radioisotopes Market?

The rising cases of cardiovascular diseases are expected to propel the growth of the nuclear medicine radioisotope market going forward. Cardiovascular diseases refer to a group of diseases that affect the heart and blood vessels. The rising cases of cardiovascular diseases are due to sedentary lifestyles, poor dietary habits, increasing rates of obesity, and aging populations. The nuclear medicine radioisotopes are invaluable in diagnosing, evaluating, and managing cardiovascular diseases with detailed insights into cardiac function, perfusion, and tissue viability, which are essential for accurate diagnosis and effective treatment planning. For instance, in January 2024, according to the American Heart Association, a US-based non-profit organization, the age-adjusted death rate from cardiovascular disease increased to 233.3 per 100,000 in 2024, up 4.0% from 224.4 per 100,000 in 2023. Therefore, the rising cases of cardiovascular diseases are driving the growth of the nuclear medicine radioisotope industry.

Key Players In The Global Nuclear Medicine Radioisotopes Market

Major companies operating in the nuclear medicine radioisotopes market are Cardinal Health Inc., Bayer AG, Siemens Healthineers AG, GE HealthCare Technologies, BWX Technologies Inc., Mallinckrodt Pharmaceuticals, Bracco Imaging S.p.A., Lantheus Holdings Inc., Curium Pharma, Australian Nuclear Science and Technology Organisation (ANSTO) Health, Eckert & Ziegler Strahlen, NorthStar Medical Radioisotopes, NTP Radioisotopes, Shine Medical Technologies Inc., Jubilant DraxImage Inc., Isotopia Molecular Imaging Ltd., Eczacıbaşı-Monrol Nuclear Products, International Isotopes Inc., Polatom Sp. z o.o., Radiomedix Inc., Positron Corporation

Global Nuclear Medicine Radioisotopes Market Trends and Insights

Major companies operating in the nuclear medicine radioisotopes market are focusing on developing innovative solutions such as next-generation theranostic radiopharmaceuticals to enhance precision imaging and targeted treatment. Next-generation theranostic radiopharmaceuticals are advanced radioactive agents designed to both detect and precisely treat diseases by targeting specific cells in the body with high accuracy. For instance, in November 2025, the University of California, a US-based research university, launched a completely independent Department of Nuclear Medicine & Theranostics, rather than keeping nuclear medicine under a broader radiology umbrella. This new department aims to accelerate the integration of advanced imaging and targeted radiopharmaceutical therapies. It also strengthens research, education, and clinical programs to advance precision medicine and drive innovations in theranostic treatments.

What Are Latest Mergers And Acquisitions In The Nuclear Medicine Radioisotopes Market?

In April 2024, Telix Pharmaceuticals Limited, an Australia-based biotechnology company, acquired ARTMS for an undisclosed amount. With this acquisition, Telix Pharmaceuticals aimed to strengthen its nuclear medicine capabilities, optimize production procedures, and broaden its range of diagnostic and therapeutic radiopharmaceuticals. ARTMS is a Canada-based company providing novel radioisotope technology and is involved in nuclear medicine radioisotopes.

Regional Insights

North America was the largest region in the nuclear medicine radioisotopes market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Nuclear Medicine Radioisotopes Market?

The nuclear medicine radioisotopes market consists of sales of yttrium-90, indium-111, carbon-11, samarium-153, and strontium-89. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Nuclear Medicine Radioisotopes Market Report 2026?

The nuclear medicine radioisotopes market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the nuclear medicine radioisotopes industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.